Form 4: DBV Technologies CEO Daniel Tasse Awarded Stock Options
SEC Form 4 Filing
DBV Technologies CEO Daniel Tasse was granted 813,200 stock options on December 4, 2024, which will vest in four equal annual installments starting December 4, 2025.
Summary
- Daniel Tasse, the CEO of DBV Technologies, was granted 813,200 stock options on December 4, 2024.
- The exercise price for these options is $0.89 per share, reflecting a conversion from Euros to USD at a rate of $1.0511 per Euro.
- The options will vest in four equal annual installments, beginning on December 4, 2025, and are contingent on Mr. Tasse's continued service with the company.
- The options expire on December 4, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of DBV Technologies' stock price.
- If the CEO leaves the company before the options fully vest, he may forfeit some or all of the options.
Future Outlook
The stock options will vest over the next four years, contingent on the CEO's continued service.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- The vesting schedule of four years is also typical, encouraging long-term commitment from the executive.
- The exercise price is set at a fixed value, which is common for stock options.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 12/04/2024 | Date of the stock option grant to Daniel Tasse. |
| 12/04/2025 | First vesting date for the stock options. |
| 12/04/2034 | Expiration date of the stock options. |
| 12/06/2024 | Date the form was signed by the Attorney-in-Fact. |
Keywords
stock options, executive compensation, DBV Technologies, Daniel Tasse, vesting, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.